XLO insider filings
Xilio Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-02. Screen XLO transaction legs live →
Insider transaction summary — last 90 days
2026-07-29 to 2026-10-27, from the filings listed below: 2 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Houvras Yariv — CHIEF MEDICAL OFFICER | 2 | — | — | 1 |
Recent insider filings — Xilio Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-02 | 3 | Houvras Yariv — CHIEF MEDICAL OFFICER | Holdings only — no transactions reported | EDGAR |
| 2026-10-02 | 4 | Houvras Yariv — CHIEF MEDICAL OFFICER | Grant/award (A): 105,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Curran Daniel J. — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Bello Akintunde Olatokumbo — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Xu Yuan — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | ROSS ROBERT W. — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Brennan Aoife — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Bonstein Sara — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Shannon James Samuel — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2026-04-16 | 4 | Blanchard Cheryl R — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-03-30 | 4 | Shannon James Samuel — Director | Purchase (P): 5,000 @ $8.79 | EDGAR |
| 2026-02-17 | 4 | GILEAD SCIENCES, INC. — 10% owner | Purchase (P): 3,739,000 (derivative) @ $0.53 | EDGAR |
| 2026-01-05 | 4 | Luptakova Katarina — CHIEF MEDICAL OFFICER | Option exercise (M): 16,625 · Grant/award (A): 451,885 (derivative) @ $0 · Option exercise (M): 16,625 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Brennan Kevin M. — SVP, FINANCE AND ACCOUNTING | Option exercise (M): 5,000 · Sale (S): 1,826 @ $0.64 · Grant/award (A): 95,221 (derivative) @ $0 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Frankenfield Christopher James — Chief Financial Officer | Option exercise (M): 19,375 · Sale (S): 7,030 @ $0.64 · Grant/award (A): 668,789 (derivative) @ $0 · Option exercise (M): 19,375 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Russo Rene — PRESIDENT AND CEO, Director | Option exercise (M): 44,250 · Grant/award (A): 1,500,258 (derivative) @ $0 · Option exercise (M): 44,250 (derivative) @ $0 | EDGAR |
| 2025-12-01 | 4 | GILEAD SCIENCES, INC. — 10% owner | Option exercise/expiry (X): 13,335,000 (derivative) @ $0.75 · Option exercise/expiry (X): 13,335,000 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Brennan Kevin M. — SVP, FINANCE AND ACCOUNTING | Grant/award (A): 131,700 (derivative) @ $0 · Disposition to issuer (D): 55,000 (derivative) · Grant/award (A): 55,000 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Grant/award (A): 25,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · +1 more | EDGAR |
| 2025-11-25 | 4 | Luptakova Katarina — CHIEF MEDICAL OFFICER | Grant/award (A): 625,000 (derivative) @ $0 · Disposition to issuer (D): 44,210 (derivative) · Grant/award (A): 44,210 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Grant/award (A): 15,000 (derivative) · Disposition to issuer (D): 35,000 (derivative) · +5 more | EDGAR |
| 2025-11-25 | 4 | Frankenfield Christopher James — Chief Financial Officer | Grant/award (A): 925,000 (derivative) @ $0 · Disposition to issuer (D): 155,090 (derivative) · Grant/award (A): 155,090 (derivative) · Disposition to issuer (D): 23,786 (derivative) · Grant/award (A): 23,786 (derivative) · Disposition to issuer (D): 37,296 (derivative) · +11 more | EDGAR |
| 2025-11-25 | 4 | Russo Rene — PRESIDENT AND CEO, Director | Grant/award (A): 2,075,000 (derivative) @ $0 · Disposition to issuer (D): 239,703 (derivative) · Grant/award (A): 239,703 (derivative) · Disposition to issuer (D): 473,334 (derivative) · Grant/award (A): 473,334 (derivative) · Disposition to issuer (D): 135,134 (derivative) · +11 more | EDGAR |
| 2025-06-18 | 4 | Russo Rene — PRESIDENT AND CEO, Director | Purchase (P): 36,289 @ $0.68 | EDGAR |
| 2025-06-18 | 4/A | Russo Rene — PRESIDENT AND CEO, Director | Holdings only — no transactions reported | EDGAR |
| 2025-06-18 | 4 | Shannon James Samuel — Director | Purchase (P): 45,000 @ $0.69 · Purchase (P): 25,000 @ $0.69 | EDGAR |
| 2025-06-12 | 4 | Curran Daniel J. — Director | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Xu Yuan — Director | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Bello Akintunde Olatokumbo — Director | Grant/award (A): 62,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Rossi Christina — Director | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | ROSS ROBERT W. — Director | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Brennan Aoife — Director | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Bonstein Sara — Director | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Shannon James Samuel — Director | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Clancy Paul J — Director | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | GILEAD SCIENCES, INC. — 10% owner | Purchase (P): 13,335,000 (derivative) · Purchase (P): 13,335,000 (derivative) · Purchase (P): 13,335,000 (derivative) · Purchase (P): 13,335,000 (derivative) | EDGAR |
| 2025-04-16 | 4 | Frankenfield Christopher James — Chief Financial Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2025-04-16 | 4 | Russo Rene — PRESIDENT AND CEO, Director | Grant/award (A): 190,000 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | Frankenfield Christopher James — Chief Financial Officer | Option exercise (M): 19,375 · Sale (S): 6,954 @ $0.98 · Option exercise (M): 19,375 (derivative) @ $0 · Grant/award (A): 251,000 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | Luptakova Katarina — CHIEF MEDICAL OFFICER | Option exercise (M): 16,625 · Option exercise (M): 16,625 (derivative) @ $0 · Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | Brennan Kevin M. — SVP, FINANCE AND ACCOUNTING | Option exercise (M): 5,000 · Sale (S): 1,803 @ $0.98 · Option exercise (M): 5,000 (derivative) @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | Russo Rene — PRESIDENT AND CEO, Director | Option exercise (M): 44,250 · Option exercise (M): 44,250 (derivative) @ $0 · Grant/award (A): 638,000 (derivative) @ $0 | EDGAR |
| 2024-12-19 | 4 | GILEAD SCIENCES, INC. — 10% owner | Purchase (P): 1,759,978 @ $1.04 · Purchase (P): 6,092,816 (derivative) @ $1.04 | EDGAR |
| 2024-10-02 | 4 | Brennan Kevin M. — SVP, FINANCE AND ACCOUNTING | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2024-08-06 | 4 | Frankenfield Christopher James — Chief Operating Officer | Grant/award (A): 52,000 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Curran Daniel J. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Rossi Christina — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | ROSS ROBERT W. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Brennan Aoife — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Bonstein Sara — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Shannon James Samuel — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Clancy Paul J — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Xilio Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-23 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-24 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-02-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-08 | 8-K | 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=XLO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs